GE HealthCare Technologies Inc

GE Healthcare Technologies, Inc. operates as a holding company with interest in providing medical technology, pharmaceutical diagnostics and digital solutions. Its operating segments include Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Ultrasound segment offers screening, diagnosis, treatment and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company was founded on May 16, 2022 and is headquartered in Chicago, IL.

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GE HealthCare posts robust Q4 results, eyes growth opportunities

GE HealthCare Technologies Inc delivered a strong Q4 2022 performance with notable organic revenue growth and margin expansion.
While facing challenges such as COVID-related impacts and debt interest, the company is well-positioned for growth through pricing strategies and market demand.
Opportunities lie in continued revenue growth, margin expansion, and product innovations, supported by strong market demand and strategic initiatives.
Overall, GE HealthCare's focus on performance improvement, innovation, and financial discipline sets a positive trajectory for future growth and competitiveness.

GE HealthCare reports robust Q1 earnings, eyes growth opportunities

GE HealthCare Technologies Inc delivered strong financial results in Q1 2023, with revenue growth, margin improvement, and reaffirmed guidance for the full year. The company's focus on innovation, technology investments, and strategic acquisitions positions it well for future growth.

GE HealthCare reports strong Q2 earnings, eyes precision care growth

GE HealthCare Technologies delivered strong financial performance in Q2 2023, driven by revenue growth, innovation in AI technologies, and strategic investments in key segments.
While facing challenges such as margin improvements and geopolitical risks, the company remains focused on capitalizing on growth opportunities in precision care and technological advancements.
Executives emphasized a balanced approach to capital allocation, margin expansion, and long-term growth strategies, positioning GEHC for sustained success in the evolving healthcare landscape.
Overall, GEHC's Q2 earnings call highlighted a resilient business outlook, with a clear focus on driving innovation, enhancing margins, and seizing opportunities for growth and market leadership.

GE HealthCare reports solid Q3 growth, eyes opportunities amid challenges

GE HealthCare Technologies Inc reported strong Q3 2023 performance with revenue growth, margin expansion, and strategic collaborations.
The company faces challenges in capital spending sentiment, margin targets, and managing balance sheet risks.
Opportunities for growth include new product launches, market focus, and upcoming investor engagements.
Overall, GEHC's resilience, operational improvements, and growth strategies position it well for future success.

GE HealthCare reports robust earnings, eyes growth through innovation

GE HealthCare Technologies Inc delivered strong financial performance in Q4 2023 and full-year 2023, driven by organic growth, strategic acquisitions, and margin expansion initiatives.
While facing challenges such as anticipated market declines and macroeconomic uncertainties, the company is well-positioned to leverage opportunities in increased demand, innovative technologies, and strategic partnerships.
By focusing on driving value through innovation, sustainability, and strategic investments, GE HealthCare is poised for continued growth and market leadership in the healthcare technology sector.
The outlook for 2024 indicates a positive trajectory with anticipated revenue growth, margin expansion, and a commitment to delivering high-value solutions to customers, supported by a strong financial foundation.

GE Healthcare reports steady Q1 performance amidst global challenges

GE Healthcare Technologies showcased a mixed performance in Q1 2024, with flat organic revenue growth and varied segment results.
The company remains focused on strategic alliances, margin initiatives, and cost savings to support EBIT expansion and solid margin performance.
Challenges in China sales and the need for clarity on the stimulus package present uncertainties, while opportunities lie in segment growth and new product introductions.

GE HealthCare reports steady Q2 growth amidst China challenges

GE HealthCare Technologies Inc delivered solid Q2 performance with growth in key segments like Patient Care Solutions and Pharmaceutical Diagnostics. Despite challenges in China, the company remains focused on driving margin expansion and innovation for sustained growth.

GE HealthCare reports steady Q3 growth amidst China market challenges

GE HealthCare Technologies Inc delivered a solid financial performance in Q3 2024, with 1% organic revenue growth and strong margin performance.
While facing challenges in the slow recovery of the China market, the company showcased strengths in free cash flow generation and technological innovations.
Future opportunities lie in margin expansion, growth initiatives like Flyrcado and AI solutions, and market differentiation through innovative healthcare technologies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GE Healthcare Technologies, Inc. engages in the development and manufacturing of medical technology, pharmaceutical diagnostics, and digital solutions. It operates through the following segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Ultrasound segment offers screening, diagnosis, treatment, and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services, and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company’s history roots back to the year 1892 and it was incorporated on May 16, 2022 and is headquartered in Chicago, IL.

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), is announcing today that President and Chief Executive Officer, Peter Arduini, and Vice President and Chief Financial Officer, Jay Saccaro, will hold a fireside chat from the RSNA 2023 annual meeting on Wednesday, November 29th at 9:15 am ET/8:15 am CT. The discussion will be hosted by Joanne Wuensch, Managing Director, Equity Research – Medical Technology at Citi. This live webcast can be accessed by visiting GE HealthCare's Investor Rela.

GE HealthCare to Hold Fireside Chat with Citi Medtech Analyst at RSNA 2023

CHICAGO--(BUSINESS WIRE)--As demand for Theranostic care increases, GE HealthCare and BAMF Health are excited to announce a collaboration aimed at enabling BAMF Health to scale turnkey offerings inclusive of leading GE HealthCare technologies and services. The goal of the collaboration is to ensure an agile go-to-market approach to enhance the adoption of Theranostics solutions in the U.S. The arrangement supports a shared interest in better patient outcomes made possible through advanced diagn.

Expanding the Reach of Care for Cancer and Other Disease States: BAMF Health and GE HealthCare collaborate to enable sustainable and scalable solutions for growth in Theranostics

Johnson & Johnson

Medtronic

Artificial intelligence is expected to transform the healthcare sector radically over the next 10 years. These three companies are leading the charge to implement AI into their product offerings and day-to-day operations.

3 Brilliant Artificial Intelligence Stocks to Buy and Hold Forever

Masimo

CHICAGO & IRVINE, Calif.--(BUSINESS WIRE)--GE HealthCare and Masimo announced a joint agreement to integrate Masimo SET® into the GE HealthCare Portrait Mobile platform.

GE HealthCare and Masimo Collaborate to Bring Masimo SET® Pulse Oximetry to the Wireless and Wearable GE HealthCare Portrait Mobile Platform

GE HealthCare Technologies Inc. (NASDAQ:GEHC ) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Carolynne Borders - Head-Investor Relations Peter Arduini - President & Chief Executive Officer Jay Saccaro - Vice President & Chief Financial Conference Call Participants Vijay Kumar - Evercore Joanne Wuensch - Citi Anthony Petrone - Mizuho Patrick Wood - Morgan Stanley Larry Biegelsen - Wells Fargo Ryan Zimmerman - BTIG Jason Bednar - Piper Sandler Suraj Kalia - Oppenheimer Operator Good day and welcome to GE HealthCare's Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

GE HealthCare Technologies Inc. (GEHC) Q3 2023 Earnings Call Transcript

GE HealthCare's revenue growth is expected to benefit from healthy order bookings and backlog levels, along with easing supply chain challenges. The company's revenues should also benefit from volume growth fueled by good end-market demand and strong execution. Easing inflation, price increases, and volume leverage are expected to help margin growth in the coming quarters.

GE HealthCare: Good Execution And Potential For A Re-Rating

CHALFONT ST GILES, England--(BUSINESS WIRE)--GE HealthCare Announces New Data Validating Artificial Intelligence Models for Predicting Patient Response to Immunotherapies.

GE HealthCare Announces New Data Validating Artificial Intelligence Models for Predicting Patient Response to Immunotherapies

GE HealthCare's Q3 2023 financial results showed a 5% increase in revenue and a 90 basis point increase in gross margin. The company raised the low end of its Adj EPS guidance for 2023. GE HealthCare is facing challenges in China but is still performing better than competitors in the region, gaining market share.

GE HealthCare: Great Quarter, Upside Remains

A jump in elective surgeries delayed during the COVID-19 pandemic boosted demand for medical equipment made by GE HealthCare Technologies (GEHC), and shares advanced.

GE HealthCare's Results Beat Estimates on Higher Demand for Medical Equipment

GE HealthCare Technologies has posted third-quarter earnings that beat expectations and revised its full-year guidance, sending its shares higher on Tuesday. The Chicago-based medical devices company, which was spun out of General Electric (NYSE:GE) in January, reported the bulk of its revenue from its Imaging operation, which grew revenues by 5% to $2.6 billion on the back of supply chain improvements, pricing, and new product innovations.

GE HealthCare stock rallies on 3Q earnings beat

GE HealthCare Technologies Inc on Tuesday beat Wall Street expectations for third-quarter profit as a continued recovery in demand for surgical procedures boosted sales of its medical devices.

GE HealthCare beats quarterly profit estimates on imaging device demand

The company posts adjusted third-quarter earnings per share of 99 cents from sales of $4.8 billion, beating expectations for 90 cents and $4.8 billion, respectively.

GE Healthcare Profit Margins Top Wall Street Estimates

GE HealthCare Technologies Inc. GEHC, +0.11% said Tuesday it had net income of $375 million, or 83 cents a share, for the third quarter, down from $487 million, or $1.07 a share, in the year-earlier period. Adjusted per-share earnings came to 99 cents, ahead of the 90 cent FactSet consensus.

GE HealthCare beats Q3 profit estimates

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), a leading global precision care innovator, today reported financial results for the third quarter ended September 30, 2023. GE HealthCare President and CEO Peter Arduini said, “We delivered another strong quarter of revenue growth with margin performance demonstrating progress on productivity and price. Cash performance was strong as we leveraged lean principles to improve inventory management. We remain confident in our 2023 outlook as we.

GE HealthCare Reports Third Quarter 2023 Financial Results

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) and reLink Medical today announced a collaboration to deliver asset management solutions to healthcare providers to help reduce medical device waste, increase operational efficiency and maximize their equipment utilization. This collaboration features a standardized medical equipment disposition solution involving selling, recycling or donating equipment that is no longer needed. Each year, healthcare providers retire approximately ten perc.

GE HealthCare and reLink Medical Collaborate to Help Reduce Medical Device Waste for Healthcare Providers

CHICAGO--(BUSINESS WIRE)--GE HealthCare has topped a U.S. Food and Drug Administration (FDA) list of artificial intelligence (AI) enabled medical devices with 58 listed 510(k) clearances or authorizations to date in the United States. GE HealthCare also topped the list when it was updated by the FDA in 2022. AI is central to the company's digital strategy, which is focused on its precision care framework that includes smart devices, targeted therapies, a disease-specific focus, and digital solu.

GE HealthCare Tops List with Highest Number of AI-Enabled Medical Device Authorizations, Developing Innovative Solutions for Precision Care

SAN FRANCISCO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will showcase some of the latest innovations designed to help clinicians in the treatment of cardiovascular disease at the 2023 Transcatheter Cardiovascular Therapeutics conference (TCT) which will take place October 23-26 in San Francisco, CA. In modern healthcare today, cardiovascular disease (CVD) continues to grow in prevalence, with CVDs continuing to be the leading cause of death globally.1 As clinicians work to treat CVD, cardi.

GE HealthCare Announces New Innovations and Collaborations in Image Guided Therapy as part of TCT2023 Cardiology Care Pathway Showcase

GE HealthCare (GEHC) is expected to report strong organic revenue growth, banking on balanced segmental performance driven by consistent NPIs and growing customer demand.

GE HealthCare (GEHC) to Report Q3 Earnings: What's in Store?

Novo Nordisk

GE HealthCare Technologies Inc. GEHC, -2.35% on Thursday said it is teaming up with Novo Nordisk NVO, -0.58% to develop an ultrasound treatment for type 2 diabetes and obesity.

GE HealthCare teams up with Novo Nordisk to treat diabetes without drugs

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced a collaboration with Novo Nordisk to further advance the clinical and product development of peripheral focused ultrasound (PFUS). This is a novel technology that has potential to specifically regulate metabolic function in the body using ultrasound that may support the treatment of chronic diseases such as type 2 diabetes and obesity. PFUS is a non-invasive type of bioelectronic medicine that uses ultrasound to activate the.

GE HealthCare and Novo Nordisk to Collaborate to Advance Novel Non-Invasive Treatment for Type 2 Diabetes and Obesity with Ultrasound

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), a leader in precision care innovation, will announce its third quarter 2023 financial results before the market opens on Tuesday, October 31, 2023. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast r.

GE HealthCare to Announce Third Quarter 2023 Results on October 31, 2023

CHICAGO--(BUSINESS WIRE)--Today, GE HealthCare (Nasdaq: GEHC) announced US FDA 510(k) clearance of Allia IGS Pulse - the latest addition to the company's image guided system (IGS) offerings. Allia IGS Pulse features a new imaging chain engineered to provide exceptional imaging at the right dose for visible impact in complex cardiology interventions regardless of patient size. In modern healthcare today, cardiovascular disease (CVD) continues to grow in prevalence, with CVDs being the leading ca.

GE HealthCare Receives FDA Clearance of Allia IGS Pulse - the Next Generation of Image-Guided Systems Designed for Cardiac Imaging Excellence

SAN FRANCISCO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced new data from a pilot study conducted with Cleveland Clinic evaluating the Portrait Mobile wireless and wearable monitoring solution. The results demonstrate that continuous patient monitoring with Portrait Mobile resulted in alarm data suitable for optimization of ward default values and further refinement on an individual basis seems likely to improve usability. The data was presented during the ASA 2023 Annual Meeti.

GE HealthCare Announces Study Results Demonstrating Portrait Mobile Continuous Monitoring Solution Performance with Patients and Care Teams in the Ward

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced it signed a $44 million contract with the Biomedical Advanced Research and Development Authority (BARDA)—part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS)—to develop and obtain regulatory clearance for next-generation advanced point-of-care ultrasound technology with new artificial intelligence (AI) applications. Technology resulting from t.

GE HealthCare Signs $44 Million Contract with BARDA to Develop Artificial Intelligence-Augmented Ultrasound Technology to Aid Clinicians in Diagnosing and Treating Traumatic Injury and Enhance National Preparedness for Mass Casualty Incidents

CHALFONT ST GILES, England--(BUSINESS WIRE)--SOFIE Biosciences and GE HealthCare Enter Licensing Agreement to Develop FAP PET Radiotracers.

News for GE HealthCare Technologies Inc Stock (GEHC)